Bill of Health 2025 Year-in-Review
Social media, pharmaceutical pricing, neurotech, mental health, abortion, psychedelics, and GLP1s generated high interest on the Bill of Health blog this year.
Published
Author
Photo Credit
Name Here
Share
Social media, pharmaceutical pricing, neurotech, mental health, abortion, psychedelics, and GLP1s generated high interest on the Bill of Health blog this year.
We’ve broken down the sampling of our most-read articles into months, so please enjoy 12 months of Bill of Health highlights below.
Catch up on any coverage you may have missed during the holiday break; we will publish again mid-January.
JANUARY
Fighting Wildfires with Chemicals: The Controversy and Danger of Flame Retardant Materials
Jan. 23
By Jessica Samuels
FEBRUARY
Innovation, Law, and Ethics in International Bioscience
Feb. 18
By Timo Minssen and Marcelo Corrales Compagnucci
MARCH
Hims? Hers? It’s Novo Nordisk’s Semaglutide Market Now
March 14
By Rebekah Ninan
APRIL
Who’s Gonna Pay? The Impact of Tariffs on Pharmaceutical Products
April 14
By Jessica Samuels
MAY
The Global Risks of America’s “Most-Favored-Nation” Drug Pricing Policy
May 22
By Ganeswar Matcha
JUNE
Ozempic, Celebrities, and TikTok: A Regulatory Nightmare Waiting to Happen?
June 26
By Abeer Malik
JULY
Medicaid Cuts Will Endanger a Lifeline for Persons with Intellectual Disabilities’ Community Integration, Empowerment, and More
July 1
By Hezzy Smith, Anne Fracht, Sam Paster, and Anna Weinberger
AUGUST
Addictive Algorithms and the Digital Fairness Act: A New Chapter in EU Public Health Policy?
Aug. 20
By Hannah van Kolfschooten
SEPTEMBER
When Evidence Burns: Abortifacient Ideology and the FDA
Sept. 19
By Julia Etkin
OCTOBER
Case v. Montana and Police Responses to Mental Health Calls
Oct. 14
By Jared Vornhagen
NOVEMBER
The PULSE of Psychedelics, Law, and Spirituality
Nov. 24
By the Petrie-Flom Center
DECEMBER
Rethinking Evidence for Psychedelics in Medicine
Dec. 5
By Eduardo Schenberg, Marion Haberkamp, and Franklin King
